WASHINGTON--(BUSINESS WIRE)-- In December 2011, Diane Bieri will step down from her role as Executive Vice President and General Counsel of the Pharmaceutical Research and Manufacturers of America (PhRMA).
Bieri took over as General Counsel in April 2007. Prior to that, she served as Deputy General Counsel from 2006 to 2007. She began her career at PhRMA as the association’s Compliance Officer in June 2004.
Upon her departure as General Counsel, Bieri plans to take maternity leave and then pursue opportunities that build on her experience in the biopharmaceutical sector, including working as a consultant for PhRMA.
“Diane has been an able and thoughtful leader of PhRMA’s legal team and we will miss her advice and counsel,” PhRMA President and CEO John J. Castellani stated. “I am pleased we will be able to continue to benefit from her expertise and wish her all success and happiness in this new phase of her career.”
“My time at PhRMA has been both challenging and rewarding,” Bieri stated. “I have been fortunate to work with many talented colleagues and to have the privilege of advocating for some of the most innovative companies in the country. My husband and I will welcome our first child in December, and after a brief sabbatical, I look forward to continuing to work with PhRMA and its members in a different capacity.”
During her tenure at PhRMA, Bieri led the legal department and the association to significant litigation victories, successfully challenging the constitutionality of a District of Columbia statute that imposed price controls on drugs sold in the District and a Vermont statute that restricted biopharmaceutical companies’ ability to purchase and use physician prescriber data to inform healthcare professionals about their medicines.
In addition, Bieri spearheaded PhRMA’s efforts to develop industry-wide standards and best practices in promotional activities, resulting in the adoption of the PhRMA Guiding Principles on Direct to Consumer Advertisements About Prescription Medicines and substantial revisions to the PhRMA Code on Interactions with Healthcare Professionals. She also served as a spokesperson on policy issues ranging from the value of biopharmaceutical marketing and DTC advertising, to companies’ efforts to build and maintain robust compliance programs, to the pro-consumer benefits of patent settlements between branded and generic pharmaceutical companies.
Before joining PhRMA, Bieri was a partner at the Washington D.C.-based law firm, Howrey LLP, specializing in antitrust and commercial litigation. She began her legal career as an associate at Howrey in 1995, after graduating cum laude from Georgetown University Law Center. She is also a 1992 summa cum laude graduate of the University of Pittsburgh, where she earned a Bachelor of Arts degree in Journalism and Political Science.
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading pharmaceutical research and biotechnology companies, which are devoted to inventing medicines that allow patients to live longer, healthier, and more productive lives. PhRMA companies are leading the way in the search for new cures. PhRMA members alone invested an estimated $49.4 billion in 2010 in discovering and developing new medicines. Industry-wide research and investment reached a record $67.4 billion in 2010.
Find PhRMA Online:
- Website – http://www.phrma.org
- facebook – www.facebook.com/PhRMA
- Blog – www.phrma.org/catalyst
- Twitter – www.Twitter.com/PhRMA and www.Twitter.com/PhRMApress
- YouTube – www.youtube.com/PhRMApress
For information on how innovative medicines save lives, visit: http://www.innovation.org
For information on the Partnership for Prescription Assistance, visit: http://www.pparx.org
For information on ensuring the flow of medicines during public health emergencies, visit http://www.rxresponse.org
CONTACT:
Pharmaceutical Research and Manufacturers of America (PhRMA)
Karl Uhlendorf, 202-835-3460
KEYWORDS: United States North America District of Columbia
INDUSTRY KEYWORDS: Health Public Policy/Government Healthcare Reform Pharmaceutical Other Policy Issues Manufacturing Public Policy Other Manufacturing
MEDIA:
| Logo |